5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Zacks highlights a constructive 2026 outlook for the small/medium Medical-Drugs industry despite pipeline setbacks, patent expirations and regulatory uncertainty, citing accelerating innovation, AI-driven drug discovery and sustained M&A. The 141-stock industry has underperformed over the past year (+1.2% vs. S&P 500 +18.9%) and trades at a trailing P/S of 2.25 (vs. S&P 6.03), while its Zacks Industry Rank is #90 (top 37%). Zacks profiles five small-cap names: Ironwood (IRWD) — apraglutide Phase III planned H1 2026, stock +178.9% last 3 months and 2026 EPS consensus up from $0.40 to $0.47; Rigel (RIGL) — net product sales +69% in first nine months of 2025, stock +46.7% and 2026 EPS consensus rose $3.70→$4.30; Soleno (SLNO) — Vykat XR ~$99m net sales since April, stock -25.7% but 2026 EPS consensus $3.10→$3.59; Marker (MRKR) — promising MT-601 data, stock +75.5% and 2026 loss/ share narrowed $4.92→$1.86; Nektar (NKTR) — rezpeg advancing toward Phase III, stock -26.0% and 2026 loss narrowed $12.17→$10.81.

Analysis

Market structure: Small/medium drugmakers with late‑stage assets and recently approved orphan drugs (IRWD, SLNO, RIGL) are short‑term winners as investor capital rotates toward high‑IRR specialty assets; CDMOs and AI‑drug discovery vendors are secondary beneficiaries. Pricing power shifts toward niche rare‑disease drugs and cell therapies where payers accept premium ASPs, tightening supply/demand for experienced manufacturing capacity and lifting valuations versus broader pharma. Cross‑asset: a biotech rally compresses high‑yield credit spreads for rated biotechs, lifts equity implied vols (expect 30–60% IV on single names around binary events), and creates mild USD softening on risk‑on flows.

Risk assessment: Key tail risks are binary trial/regulatory failures (probability 20–40% for late‑stage pivots), manufacturing scale‑up failures for cell therapies, and payer pushback on specialty pricing. Time horizons separate into immediate (days of M&A/data noise), short (weeks–months to H1 2026 readouts and EU review windows), and long (commercial ramp and multi‑year market share capture). Hidden dependencies include partner royalty streams (Linzess for IRWD), CDMO capacity for MRKR, and contingent M&A premiums; catalysts: FDA meetings, EU approval for Vykat XR, and phase‑III starts in H1 2026.

Trade implications: Favor concentrated, size‑constrained longs in IRWD and RIGL to capture commercial upside and recurring revenue — size 1.5–3% each of portfolio — hedged with puts or call spreads around H1 2026 windows. Use pair trades (long RIGL, short IBB 0.8–1.2%) to isolate idiosyncratic execution upside. For MRKR, prefer option call‑spreads (6–9 month) into H1 2026 data; avoid large directional NKTR longs until Phase‑III entry and clearer cash runway.

Contrarian angles: Consensus underweights commercial execution and payer risk — Vykat XR’s $99m launch is real but scaling to blockbuster requires formulary wins that are not priced in. IRWD’s 178% run in 3 months suggests momentum may be stretched; a >40% pullback should be used to size up. Historical parallels (post‑approval biotech pops then mean reversion) argue for hedged exposure and defined exit triggers tied to concrete commercial metrics (sales, label expansions, ORR thresholds).

Key Decisions for Investors

• Establish a 2.5% long position in IRWD now to capture apraglutide Phase III initiation and Linzess tailwinds; add up to +1.5% on any >10% pullback; hedge the position with a 12–18 month protective put at ~20% OTM or buy a 12–18 month 25% OTM LEAP call if preferring optionality.
• Establish a 2.0% long position in RIGL financed by a 1.0% short in IBB (pair trade) to isolate product execution upside from sector beta; target exit or re‑weight after H1 2026 commercial cadence update or if RIGL shares rise >50% from entry.
• Allocate 0.75% speculative long to MRKR via a 6–9 month call‑spread (buy ATM, sell 30% OTM) ahead of H1 2026 APOLLO data; liquidate if reported ORR <30% or if safety signals emerge.
• Reduce/avoid incremental exposure to NKTR; keep tactical exposure ≤0.5% until rezpeg enters Phase III and cash runway ≥12 months; cut full position if 2026 loss guidance remains worse than $10/sh or cash burn implies <9–12 months runway.